---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006284"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:57:58.148136+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024

## Summary
- Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.
- Cash, equivalents and marketable securities $41.7M at Sep 30, 2024; projected year-end cash $38-39M.
- October 2024 early warrant exercise raised $5.9M; approx. 15.4M warrants outstanding expiring June 2025.
- Soquelitinib Phase 1 atopic dermatitis trial second cohort (200mg QD) enrolling; interim data expected Dec 2024.
- Soquelitinib Phase 3 PTCL registrational trial enrolling at multiple sites; Orphan Drug and Fast Track granted.

## SEC filing metadata
- accession: 0001171843-24-006284
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/0001171843-24-006284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/f8k_111224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006284
- JSON: https://secwatch.observer/filing/0001171843-24-006284.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006284.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.